CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 202 enrolled
Drug / intervention
Remote Dielectric Sensingdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06942871
NCT06942871N/ACompleted

Non-Invasive Lung Water Monitoring Guided by Remote Dielectric Sensing Technology in the Management of Patients With Pulmonary Hypertension

Shanghai Zhongshan Hospital·observational·Posted Apr 24, 2025·Updated Apr 29, 2025

In Brief

An observational study evaluating Remote Dielectric Sensing for Pulmonary Hypertension. Completed, enrolled 202 participants across 1 site.

Detailed Summary

The investigators conducted a prospective, convenience-sampled observational pilot study, enrolling adult patients with pulmonary hypertension who were either outpatients or inpatients in the cardiology department of our hospital. The measurement of Remote Dielectric Sensing (ReDS) values was performed by ReDS™ Pro. Data were collected using the electronic medical record system of our hospital. Participants were followed up within 6 months after discharge. The primary endpoints included all-cause mortality or clinical deterioration related to pulmonary hypertension.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedApr 24, 2025
Enrollment StartApr 1, 2024
Primary CompletionMar 5, 2025
Study CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 1.2 years ago

Interventions

Remote Dielectric Sensingdevice

The lung fluid monitor Remote Dielectric Sensing (ReDS™) is the world's first non-invasive device for heart failure monitoring and management. It directly reflects lung fluid content by measuring changes in thoracic dielectric constants, with a detection range of 15% \~ 60%. The device can sensitively identify pathological states ranging from mild compensation to severe pulmonary edema. ReDS™ technology cannot directly measure pulmonary artery pressure, but changes in lung fluid content may indirectly reflect disease progression in certain types of pulmonary hypertension.